Literature DB >> 33883189

The Role of IgM Antibodies in T Cell Lymphoma Protection in a Novel Model Resembling Anaplastic Large Cell Lymphoma.

Chuancang Jiang1, Ming-Lang Zhao1, Luis Ramos2, Katarzyna Dobaczewska3, Ronald Herbert4, Kristen Hobbie5, Zbigniew Mikulski3, Laurent Verkoczy6, Marilyn Diaz7,2.   

Abstract

MRL/lpr mice typically succumb to immune complex-mediated nephritis within the first year of life. However, MRL/lpr mice that only secrete IgM Abs because of activation-induced deaminase deficiency (AID-/-MRL/lpr mice) experienced a dramatic increase in survival. Further crossing of these mice to those incapable of making secretory IgM (μS mice) generated mice lacking any secreted Abs but with normal B cell receptors. Both strains revealed no kidney pathology, yet Ab-deficient mice still experienced high mortality. In this article, we report Ab-deficient MRL/lpr mice progressed to high-grade T cell lymphoma that can be reversed with injection of autoreactive IgM Abs or following adoptive transfer of IgM-secreting MRL/lpr B cells. Anti-nuclear Abs, particularly anti-dsDNA IgM Abs, exhibited tumor-killing activities against a murine T cell lymphoma cell line. Passive transfers of autoreactive IgM Abs into p53-deficient mice increased survival by delaying onset of T cell lymphoma. The lymphoma originated from a double-negative aberrant T cell population seen in MRL/lpr mice and most closely resembled human anaplastic large cell lymphoma. Combined, these results strongly implicate autoreactive IgM Abs in protection against T cell lymphoma.
Copyright © 2021 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33883189      PMCID: PMC8113120          DOI: 10.4049/jimmunol.2001279

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

Review 1.  ALCL by any other name: the many facets of anaplastic large cell lymphoma.

Authors:  Lina Irshaid; Mina L Xu
Journal:  Pathology       Date:  2019-11-06       Impact factor: 5.306

Review 2.  New developments in Toll-like receptor targeted therapeutics.

Authors:  Dympna J Connolly; Luke A J O'Neill
Journal:  Curr Opin Pharmacol       Date:  2012-06-28       Impact factor: 5.547

Review 3.  Protective autoimmunity in cancer (review).

Authors:  E Toubi; Y Shoenfeld
Journal:  Oncol Rep       Date:  2007-01       Impact factor: 3.906

Review 4.  Genetics of systemic autoimmunity in mouse models of lupus.

Authors:  D H Kono; A N Theofilopoulos
Journal:  Int Rev Immunol       Date:  2000       Impact factor: 5.311

5.  Prevalence and pattern of antinuclear autoantibodies in 347 patients with non-Hodgkin's lymphoma.

Authors:  Stephanie Guyomard; Gilles Salles; Marie Coudurier; Hugues Rousset; Bertrand Coiffier; Jacques Bienvenu; Nicole Fabien
Journal:  Br J Haematol       Date:  2003-10       Impact factor: 6.998

6.  Autoimmune disease and subsequent urological cancer.

Authors:  Xiangdong Liu; Jianguang Ji; Asta Forsti; Kristina Sundquist; Jan Sundquist; Kari Hemminki
Journal:  J Urol       Date:  2012-12-08       Impact factor: 7.450

7.  Abrogation of lupus nephritis in activation-induced deaminase-deficient MRL/lpr mice.

Authors:  Chuancang Jiang; Julie Foley; Natasha Clayton; Grace Kissling; Micheal Jokinen; Ronald Herbert; Marilyn Diaz
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

Review 8.  Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas.

Authors:  H J Gruss; S K Dower
Journal:  Blood       Date:  1995-06-15       Impact factor: 22.113

9.  Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions.

Authors:  W F Davidson; T Giese; T N Fredrickson
Journal:  J Exp Med       Date:  1998-06-01       Impact factor: 14.307

10.  Protective Roles of Natural IgM Antibodies.

Authors:  Caroline Grönwall; Jaya Vas; Gregg J Silverman
Journal:  Front Immunol       Date:  2012-04-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.